Current and Emerging Treatment Landscape of mHSPC

Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.

Now Viewing

EP: 1.Current and Emerging Treatment Landscape of mHSPC

Related Videos

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.